ethosuximide has been researched along with Parkinson Disease, Secondary in 2 studies
Ethosuximide: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
ethosuximide : A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Following the demonstration of an anti-tremor effect of ethosuximide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkey model, we have tested the effect of this drug in 10 patients with typical parkinsonian tremor." | 9.07 | Ethosuximide and tremor in Parkinson's disease: a pilot study. ( Bédard, PJ; Gomez-Mancilla, B; Pourcher, E, 1992) |
| "Based on the hypothesis that low-threshold calcium conductance in the thalamus might be involved in the pathophysiology of parkinsonian tremor, ethosuximide was given chronically to a monkey previously treated with MPTP and displaying exceptionally a typical rest tremor." | 7.68 | Effect of ethosuximide on rest tremor in the MPTP monkey model. ( Bédard, PJ; Boucher, R; Gomez-Mancilla, B; Latulippe, JF, 1992) |
| "Following the demonstration of an anti-tremor effect of ethosuximide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkey model, we have tested the effect of this drug in 10 patients with typical parkinsonian tremor." | 5.07 | Ethosuximide and tremor in Parkinson's disease: a pilot study. ( Bédard, PJ; Gomez-Mancilla, B; Pourcher, E, 1992) |
| "Based on the hypothesis that low-threshold calcium conductance in the thalamus might be involved in the pathophysiology of parkinsonian tremor, ethosuximide was given chronically to a monkey previously treated with MPTP and displaying exceptionally a typical rest tremor." | 3.68 | Effect of ethosuximide on rest tremor in the MPTP monkey model. ( Bédard, PJ; Boucher, R; Gomez-Mancilla, B; Latulippe, JF, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pourcher, E | 1 |
| Gomez-Mancilla, B | 2 |
| Bédard, PJ | 2 |
| Latulippe, JF | 1 |
| Boucher, R | 1 |
1 trial available for ethosuximide and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Ethosuximide and tremor in Parkinson's disease: a pilot study.
Topics: Adult; Aged; Antipsychotic Agents; Ethosuximide; Female; Humans; Male; Middle Aged; Neurologic Exami | 1992 |
1 other study available for ethosuximide and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Effect of ethosuximide on rest tremor in the MPTP monkey model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Diltiazem; Dopamine Agents; Dose-Response Rel | 1992 |